CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announced the appointment of Paul Fonteyne to its Board of Directors. Mr. Fonteyne’s deep commercialization and leadership experience will support the company’s global plans to bring new treatments to people with neurodegenerative diseases.
“Paul is a true leader in the health care industry with a proven record of success in building effective teams, launching global products and running commercial organizations focused on delivering for patients,” said Justin Klee, Co-CEO and Co-Founder of Amylyx. “His experience will be an incredibly valuable addition to the Amylyx Board as we look to bring our investigational product, AMX0035, to people living with neurodegenerative disease.”
Mr. Fonteyne has more than thirty years of experience in the pharmaceutical industry, including in leadership positions focused on the commercialization of innovative treatments for patients around the globe. Most notably, he was with Boehringer Ingelheim for more than fifteen years (2003-2018), where he served as the U.S. President and CEO for seven years, and subsequently Chairman until his retirement in January 2019. During his tenure at Boehringer Ingelheim, Fonteyne helped drive the company's annual top line sales in the USA significantly upwards and oversaw the successful U.S. launch of the company’s top selling products. Prior, he held commercial leadership roles at Merck and Co. Inc. and Abbott Laboratories.
“Joining the Amylyx Board gives me the opportunity to contribute to the fight to find effective treatments for ALS and other neurodegenerative disease patients across the globe,” said Paul Fonteyne. “I am excited to offer my experience launching many products to the Amylyx leadership team as we continue to press ahead for people with Neurodegenerative disease.”
“Justin and I greatly admire Paul’s leadership, commercial acumen and patient-centric approach in healthcare,” said Josh Cohen, Co-CEO, Chairman and Co-Founder of Amylyx. “Paul’s extensive global commercial experience expands our Board’s expertise as we move into a new and critical phase for Amylyx.”
Fonteyne also serves on the boards of several clinical stage biotechnology companies including Gelesis, DalCor (Chairman), Apellis and Ypsomed AG, a device company. Previously, he served on the boards of National Pharmaceutical Council, PhRMA, ResTORbio and AMAG Pharmaceuticals. He received an M.S. in Chemical Engineering from the University of Brussels and an MBA from Carnegie Mellon University.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. For more information, visit www.amylyx.com and follow us on LinkedIn and Twitter.